the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Fennec helicopter’s deviated path contributed to the collision with HOM copter – final report

PETALING JAYA: The collision involving two Royal Malaysian Navy (TLDM) helicopters in Lumut, Perak, which resulted in the loss of 10 officers and personnel were caused by two factors.

Navy chief Admiral Tan Sri Abdul Rahman Ayob said that the Eurocopter Fennec was not at the designated altitude and heading, and it entered the HOM (M503-3) aircraft’s flight path, as reported by New Straits Times.

“The secondary factor was the crew of HOM (M503-3) helicopter was too focused on changing direction and could not react quickly enough to avoid the collision.”

He also confirmed that no human error was found in their investigation, “the findings indicate that the aircraft was at an incorrect altitude.”

He added that the Fennec aircraft did not have a black box, so no data can conclude human error by the pilot.

“What we can conclude is that the Fennec was at the incorrect altitude and position.”

The AW139 aircraft was confirmed to have no technical problems based on the Black Box Analysis Report.

The Fennec aircraft, which did not have a black box, was determined to have no technical problems based on visual and audio analysis as well as documentation.

The HOM (M503-3) and Fennec crashed around 9:32am during the 90th RMN Day parade at the base.

The AW139 helicopter crashed onto the steps of the Lumut Stadium, while the Fennec aircraft plunged into the swimming pool of the Lumut Sports Complex.

ALSO READ: Dual helicopter collision kills all 10 onboard: RMN (Updated)

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings